Motiva Flora tissue expander leverages Establishment Labs’ patented SmoothSilk surface technology, along with an RFID-enabled port
Late-generation models of silicone gel-filled prostheses. (Credit: FDA/Wikipedia.)
Establishment Labs has rolled out its Motiva Flora tissue expander device in Europe and other CE Mark countries, in a symposium at the London Breast Meeting.
Motiva Flora tissue expander is said to provide potential improvements in imaging, treatment, and overall clinical outcomes and patient satisfaction.
It leverages the company’s patented SmoothSilk surface technology, along with an RFID-enabled, non-magnetic integrated port.
The SmoothSilk surface technology includes a bioengineered nano-surface that showed a low rate of capsular contracture and no reported cases of BIA-ALCL till date.
The London Breast Meeting chair Jian Farhadi said: “The early clinical experience with Flora shows that this RFID-enabled device can make a meaningful difference in how women are treated during post-mastectomy reconstruction and importantly, in women’s comfort during and after treatment.
“The surface biocompatibility, the ability to image with MRI, and the possibilities that a non-ferrous construction open up in oncology treatment put Flora ahead of any other tissue expander currently available.”
In June last year, Establishment Labs has secured CE mark approval for its Motiva Flora tissue expander, and is currently not approved in the US.
The tissue expander is claimed to be the only product with an integrated non-magnetic RFID port that enables safe use alongside MRI scanning.
Establishment Labs is focused on women’s health and wellness, particularly in breast aesthetics and reconstruction.
The medical technology firm offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants to provide improved aesthetic and clinical outcomes.
The company claimed that more than 1.6 million Motiva Implants have been used by the plastic surgeons in more than 80 countries, since their launch in 2010.
Establishment Labs founder and chief executive officer Juan José Chacón-Quirós said: “In Europe, breast reconstruction represents 20% or more of the breast implant market.
“Flora is a significant advancement in tissue expander technology, and we expect to take significant market share as we have in the past: by commercializing real innovation that makes a significant difference in women’s lives.
“With new options that can lead to better outcomes, we expect to expand the global market for reconstruction.”
Source: Company Press Release